A Phase I/II Dose Escalation Study of the CDK4/6 Inhibitor, Palbociclib in Combination With Cetuximab and Intensity Modulated Radiation Therapy (IMRT) for Locally Advanced Unresectable Squamous Cell Carcinoma of the Head and Neck
Phase of Trial: Phase I/II
Latest Information Update: 08 Sep 2017
At a glance
- Drugs Cetuximab (Primary) ; Palbociclib (Primary)
- Indications Head and neck cancer; Squamous cell cancer
- Focus Adverse reactions
- 31 Aug 2018 Biomarkers information updated
- 03 Sep 2017 Status changed from not yet recruiting to recruiting.
- 26 Mar 2017 Planned initiation date changed from 1 Feb 2017 to 1 May 2017.